Metabolon

Metabolon Achieves "Great Place To Work"® Certification

Retrieved on: 
Wednesday, September 6, 2023
Metabolomics, Growth, Medicine, Great Places, Management, Metabolon

MORRISVILLE, N.C., Sept. 6, 2023 /PRNewswire/ -- Metabolon, Inc. is proud to be certified by Great Place To Work®.  The prestigious certification is based entirely on current employees' experience working at Metabolon, where 83% of employees said Metabolon is a great place to work, which is 26% higher than the average U.S.-based company. 

Key Points: 
  • Independent survey validates that Metabolon employees are highly invested in the company's mission, growth, and technology
    MORRISVILLE, N.C., Sept. 6, 2023 /PRNewswire/ -- Metabolon, Inc. is proud to be certified by Great Place To Work®.
  • The prestigious certification is based entirely on current employees' experience working at Metabolon, where 83% of employees said Metabolon is a great place to work, which is 26% higher than the average U.S.-based company.
  • "Metabolon is the leader in providing metabolomics solutions that advance a wide variety of life science research, diagnostic, therapeutic, and precision medicine applications.
  • "Great Place To Work certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work.

Metabolon Achieves "Great Place To Work"® Certification

Retrieved on: 
Wednesday, September 6, 2023
Metabolomics, Growth, Medicine, Great Places, Management, Metabolon

MORRISVILLE, N.C., Sept. 6, 2023 /PRNewswire/ -- Metabolon, Inc. is proud to be certified by Great Place To Work®.  The prestigious certification is based entirely on current employees' experience working at Metabolon, where 83% of employees said Metabolon is a great place to work, which is 26% higher than the average U.S.-based company. 

Key Points: 
  • Independent survey validates that Metabolon employees are highly invested in the company's mission, growth, and technology
    MORRISVILLE, N.C., Sept. 6, 2023 /PRNewswire/ -- Metabolon, Inc. is proud to be certified by Great Place To Work®.
  • The prestigious certification is based entirely on current employees' experience working at Metabolon, where 83% of employees said Metabolon is a great place to work, which is 26% higher than the average U.S.-based company.
  • "Metabolon is the leader in providing metabolomics solutions that advance a wide variety of life science research, diagnostic, therapeutic, and precision medicine applications.
  • "Great Place To Work certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work.

Metabolon Announces Three Oral Presentations and Two Poster Presentations at the 2023 Metabolomics Society Annual Conference

Retrieved on: 
Tuesday, June 13, 2023
LC-MS/MS, Cannabinoid, Oxysterol, Molecule, QC, ECS, Nociception, ISO, Complementarity, Research, Inflammation, Appetite, PQC, Locomotion, Plasma, CLIA, Publication, Publishing, Sphingolipid, QA, Area studies, Medicine, What They Always Tell Us, Quality control, Knowledge, Memory, Medical device, Metabolomics, Metabolon, Diabetes

MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.

Key Points: 
  • MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.
  • "We are honored to present at the Metabolomics Society annual conference.
  • The presentation reports on one of the most deeply phenotyped cohort studies to date: the Qatar Metabolomics Study of Diabetes.
  • In the past year, Metabolon has launched a wide range of new targeted metabolomics panels that provide absolute quantification for important research areas.

Metabolon Announces Three Oral Presentations and Two Poster Presentations at the 2023 Metabolomics Society Annual Conference

Retrieved on: 
Tuesday, June 13, 2023
LC-MS/MS, Cannabinoid, Oxysterol, Molecule, QC, ECS, Nociception, ISO, Complementarity, Research, Inflammation, Appetite, PQC, Locomotion, Plasma, CLIA, Publication, Publishing, Sphingolipid, QA, Area studies, Medicine, What They Always Tell Us, Quality control, Knowledge, Memory, Medical device, Metabolomics, Metabolon, Diabetes

MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.

Key Points: 
  • MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.
  • "We are honored to present at the Metabolomics Society annual conference.
  • The presentation reports on one of the most deeply phenotyped cohort studies to date: the Qatar Metabolomics Study of Diabetes.
  • In the past year, Metabolon has launched a wide range of new targeted metabolomics panels that provide absolute quantification for important research areas.

Metabolon Launches Bile Acids and Short Chain Fatty Acids Targeted Panels to Advance Understanding of Microbiome and Gut Metabolome in Health and Disease

Retrieved on: 
Tuesday, April 4, 2023
FXR, Diet, Diabetes, Cholesterol, Lipid, Metabolomics, Physiology, Fermentation, TGR5, Research, Biomarker, Microbiota, Colon, Inflammatory bowel disease, Short, SFCA Lignel 46 Coach, Content discovery platform, Risk, Cancer, Medicine, SCFA, Biology, Liver, Extrapyramidal system, Health, Phenotype, Neurology, Disease, Medical imaging, Dietary supplement, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its Bile Acids and Short Chain Fatty Acids Targeted Panels that measure microbially-derived metabolites of biological significance to identify biomarkers for the prediction and early detection of disease areas, including oncology, neurology, liver, diabetes, and gastrointestinal, and gut health.

Key Points: 
  • Short Chain Fatty Acids (SCFAs) are produced in the colon by the gut microbiota and are the end products of the anaerobic fermentation of dietary fibers and protein/peptides in the small intestine.
  • Metabolon's Bile Acids Targeted Panel measures 21 metabolites and has been designed specifically to advance pre-clinical research identifying bile-acid related biomarkers in digestive, metabolic, and neurological health.
  • "Metabolon is committed to advancing scientific understanding of the human microbiome and its impact on human health.
  • Our Bile Acids and Short Chain Fatty Acids Targeted Panels address an important need for today's cutting-edge researchers and will help unlock new insights into the complex interplay between diet, gut health, and disease, paving the way for the development of more personalized, targeted therapies."

Metabolon's Metabolomic Platform and Services Cited in More Than 3,000 Peer-Reviewed Articles across Life Sciences, Pharmaceutical/Biotech, and Applied Sciences

Retrieved on: 
Wednesday, March 29, 2023
National academy, PNAS, Drug development, Nature, Population health, Complementarity, Agriculture, COVID-19, Metabolomics, Intelligence, Research, Medicine, Inflammation, Government, Science, Publication, Machine learning, Biology, Health, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., March 29, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced their metabolomics platform outputs and related services have been cited in more than 3,000 peer-reviewed journals. For more than 20 years, Metabolon has been focused on developing and refining its platform to enable the utility of metabolomics in all areas of life sciences research. The scientific insights supported by Metabolon's high-quality metabolomic outputs have allowed the company to reach this historic milestone.

Key Points: 
  • For more than 20 years, Metabolon has been focused on developing and refining its platform to enable the utility of metabolomics in all areas of life sciences research.
  • The scientific insights supported by Metabolon's high-quality metabolomic outputs have allowed the company to reach this historic milestone.
  • Metabolon continues to support active collaboration across scientific disciplines, enabling continuous growth and adoption among the life sciences and scientific innovation communities.
  • As a result, there are now more than 3,000 publications citing Metabolon's contributions, and the number continues to grow.

Metabolon's Metabolomic Platform and Services Cited in More Than 3,000 Peer-Reviewed Articles across Life Sciences, Pharmaceutical/Biotech, and Applied Sciences

Retrieved on: 
Wednesday, March 29, 2023
National academy, PNAS, Drug development, Nature, Population health, Complementarity, Agriculture, COVID-19, Metabolomics, Intelligence, Research, Medicine, Inflammation, Government, Science, Publication, Machine learning, Biology, Health, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., March 29, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced their metabolomics platform outputs and related services have been cited in more than 3,000 peer-reviewed journals. For more than 20 years, Metabolon has been focused on developing and refining its platform to enable the utility of metabolomics in all areas of life sciences research. The scientific insights supported by Metabolon's high-quality metabolomic outputs have allowed the company to reach this historic milestone.

Key Points: 
  • For more than 20 years, Metabolon has been focused on developing and refining its platform to enable the utility of metabolomics in all areas of life sciences research.
  • The scientific insights supported by Metabolon's high-quality metabolomic outputs have allowed the company to reach this historic milestone.
  • Metabolon continues to support active collaboration across scientific disciplines, enabling continuous growth and adoption among the life sciences and scientific innovation communities.
  • As a result, there are now more than 3,000 publications citing Metabolon's contributions, and the number continues to grow.

Infinity Laboratories Announces Hiring of New Senior Vice President of Commercial Operations

Retrieved on: 
Wednesday, March 22, 2023
Diversified Pharmaceutical Services, Business development, DSM, Laboratory, University, Patheon, Senior, University of Hartford, Marketing, CASTLE, Hank Nowak, Organization, Growth, Commercial Operating System, Wesleyan University, Fairfield University, Management, Science, Metabolon, Biology

CASTLE ROCK, Colo., March 22, 2023 /PRNewswire/ - Infinity Laboratories is proud to announce the hiring of Hank Nowak as our new Senior Vice President of Commercial Operations.

Key Points: 
  • CASTLE ROCK, Colo., March 22, 2023 /PRNewswire/ - Infinity Laboratories is proud to announce the hiring of Hank Nowak as our new Senior Vice President of Commercial Operations.
  • Mr. Nowak will be responsible for leading the sales and marketing strategy of the company, driving organic growth and ensuring commercial excellence.
  • "We are thrilled to have Hank join our team at Infinity Laboratories," said Joe Troxell, CEO of Infinity Laboratories.
  • Mr. Nowak is equally enthusiastic about joining the team at Infinity Laboratories.

Metabolon to Offer Targeted Panels and Assays to Aid in Dysregulated Glucose Status and Related Research

Retrieved on: 
Tuesday, February 14, 2023
Biomarker, Metabolomics, Medicine, Blood, Prediabetes, PCOS, DSM-IV codes, Diabetic neuropathy, Patient, Diabetes, Research, Insulin resistance, Health, Risk, Hypertension, Hyperglycemia, Disease, Meigs's syndrome, CVD, Cardiovascular disease, Glucose, Medical device, Medical imaging, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., Feb. 14, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its Glucose Portfolio, consisting of four specific products that each measure the metabolomic aspects of glucose tolerance and insulin resistance and offer a comprehensive characterization of what occurs at a cellular level to drive glucose metabolism, which has implications for diabetes, heart disease, and neuropathy.

Key Points: 
  • It provides confident, reproducible quantification of key analytes related to dysregulated glucose homeostasis, including lactoyl-phenylalanine which has been linked to several metabolic diseases, including diabetes.
  • Impaired Glucose Tolerance Targeted Panel : Impaired glucose tolerance is a prediabetic state of hyperglycemia that is associated with insulin resistance and an increased risk of cardiovascular disease.
  • This panel can be used with a single fasted blood sample and measures eight analytes, including glucose.
  • Salivary Glucose Single Analyte Assay : Daily monitoring of glucose levels is an essential part of managing diabetes.

Metabolon to Offer Targeted Panels and Assays to Aid in Dysregulated Glucose Status and Related Research

Retrieved on: 
Tuesday, February 14, 2023
Biomarker, Metabolomics, Medicine, Blood, Prediabetes, PCOS, DSM-IV codes, Diabetic neuropathy, Patient, Diabetes, Research, Insulin resistance, Health, Risk, Hypertension, Hyperglycemia, Disease, Meigs's syndrome, CVD, Cardiovascular disease, Glucose, Medical device, Medical imaging, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., Feb. 14, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its Glucose Portfolio, consisting of four specific products that each measure the metabolomic aspects of glucose tolerance and insulin resistance and offer a comprehensive characterization of what occurs at a cellular level to drive glucose metabolism, which has implications for diabetes, heart disease, and neuropathy.

Key Points: 
  • It provides confident, reproducible quantification of key analytes related to dysregulated glucose homeostasis, including lactoyl-phenylalanine which has been linked to several metabolic diseases, including diabetes.
  • Impaired Glucose Tolerance Targeted Panel : Impaired glucose tolerance is a prediabetic state of hyperglycemia that is associated with insulin resistance and an increased risk of cardiovascular disease.
  • This panel can be used with a single fasted blood sample and measures eight analytes, including glucose.
  • Salivary Glucose Single Analyte Assay : Daily monitoring of glucose levels is an essential part of managing diabetes.